Advisory Committee; Technical Electronic Product Radiation Safety Standards Committee; Renewal, 10108 [2021-03239]
Download as PDF
<![CDATA[
10108
Federal Register / Vol. 86, No. 31 / Thursday, February 18, 2021 / Notices
website at https://www.samhsa.gov/
about-us/advisory-councils/csatnational-advisory-council or by
contacting the CSAT National Advisory
Council Designated Federal Officer.
Council Name: SAMHSA’s Center for
Substance Abuse Treatment, National
Advisory Council.
Date/Time/Type: March 31, 2021,
1:00 p.m.–6:00 p.m. EDT, OPEN.
Place: SAMHSA, 5600 Fishers Lane,
Rockville, Maryland 20857.
Contact: Tracy Goss, Designated
Federal Officer, CSAT National
Advisory Council, 5600 Fishers Lane,
Rockville, Maryland 20857 (mail),
Telephone: (240) 276–0759, Email:
tracy.goss@samhsa.hhs.gov.
Dated: February 11, 2021.
Carlos Castillo,
Committee Management Officer, SAMHSA.
[FR Doc. 2021–03269 Filed 2–17–21; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2019–N–0803]
Advisory Committee; Technical
Electronic Product Radiation Safety
Standards Committee; Renewal
AGENCY:
Food and Drug Administration,
HHS.
Notice; renewal of Federal
advisory committee.
ACTION:
The Food and Drug
Administration (FDA) is announcing the
renewal of the Technical Electronic
Product Radiation Safety Standards
Committee by the Commissioner of
Food and Drugs (the Commissioner).
The Commissioner has determined that
it is in the public interest to renew the
Technical Electronic Product Radiation
Safety Standards Committee for an
additional 2 years beyond the charter
expiration date. The new charter will be
in effect until the December 24, 2022,
expiration date.
DATES: Authority for the Technical
Electronic Product Radiation Safety
Standards Committee (the Committee)
will expire on December 24, 2022,
unless the Commissioner formally
determines that renewal is in the public
interest.
FOR FURTHER INFORMATION CONTACT:
Patricio Garcia, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5216, Silver Spring,
MD 20993–0002, 301–796–6875, email:
Patricio.Garcia@fda.hhs.gov.
jbell on DSKJLSW7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:47 Feb 17, 2021
Jkt 253001
Pursuant
to 41 CFR 102–3.65 and approval by the
Department of Health and Human
Services pursuant to 45 CFR part 11 and
by the General Services Administration,
FDA is announcing the renewal of the
Committee. The Committee is a nondiscretionary Federal advisory
committee established to provide advice
to the Commissioner.
The Commissioner is charged with
the administration of the Radiation
Control for Health and Safety Act of
1968. This Act creates the Committee
and requires the Commissioner to
consult with the Committee before
prescribing standards for radiation
emissions from electronic products.
This Committee provides advice and
consultation to the Commissioner on the
technical feasibility, reasonableness,
and practicability of performance
standards for electronic products to
control the emission of radiation from
such products and may recommend
electronic product radiation safety
standards to the Commissioner for
consideration.
The Committee shall consist of 15
voting members, including the Chair.
Members and the Chair are selected by
the Commissioner or designee from
among authorities knowledgeable in the
fields of science or engineering
applicable to electronic product
radiation safety. Members will be
invited to serve for overlapping terms of
up to 4 years. Voting members will
include five members selected from
governmental agencies, including State
and Federal Governments, five members
from the affected industries, and five
members from the general public, of
which at least one shall be a
representative of organized labor. A
quorum shall consist of 10 members, of
which at least 3 shall be from the
general public, 3 from the government
agencies, and 3 from the affected
industries.
Further information regarding the
most recent charter and other
information can be found at https://
www.fda.gov/AdvisoryCommittees/
CommitteesMeetingMaterials/RadiationEmittingProducts/
TechnicalElectronicProduct
RadiationSafetyStandardsCommittee/
default.htm or by contacting the
Designated Federal Officer (see FOR
FURTHER INFORMATION CONTACT). In light
of the fact that no change has been made
to the committee name or description of
duties, no amendment will be made to
21 CFR 14.100.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app.). For general information
related to FDA advisory committees,
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
please visit us at https://www.fda.gov/
AdvisoryCommittees/default.htm.
Dated: February 11, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for
Policy.
[FR Doc. 2021–03239 Filed 2–17–21; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–0115]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Guidance for
Industry and Food and Drug
Administration Staff—Class II Special
Controls Guidance Document:
Automated Blood Cell Separator
Device Operating by Centrifugal or
Filtration Principle
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on the collection of
information concerning class II special
controls for an automated blood cell
separator device operating by
centrifugal or filtration separation
principle.
DATES: Submit either electronic or
written comments on the collection of
information by April 19, 2021.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before April 19,
2021. The https://www.regulations.gov
electronic filing system will accept
comments until 11:59 p.m. Eastern Time
at the end of April 19, 2021. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
SUMMARY:
E:\FR\FM\18FEN1.SGM
18FEN1
]]>Agencies
[Federal Register Volume 86, Number 31 (Thursday, February 18, 2021)]
[Notices]
[Page 10108]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-03239]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2019-N-0803]
Advisory Committee; Technical Electronic Product Radiation Safety
Standards Committee; Renewal
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; renewal of Federal advisory committee.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
renewal of the Technical Electronic Product Radiation Safety Standards
Committee by the Commissioner of Food and Drugs (the Commissioner). The
Commissioner has determined that it is in the public interest to renew
the Technical Electronic Product Radiation Safety Standards Committee
for an additional 2 years beyond the charter expiration date. The new
charter will be in effect until the December 24, 2022, expiration date.
DATES: Authority for the Technical Electronic Product Radiation Safety
Standards Committee (the Committee) will expire on December 24, 2022,
unless the Commissioner formally determines that renewal is in the
public interest.
FOR FURTHER INFORMATION CONTACT: Patricio Garcia, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 5216, Silver Spring, MD 20993-0002, 301-
796-6875, email: [email protected].
SUPPLEMENTARY INFORMATION: Pursuant to 41 CFR 102-3.65 and approval by
the Department of Health and Human Services pursuant to 45 CFR part 11
and by the General Services Administration, FDA is announcing the
renewal of the Committee. The Committee is a non-discretionary Federal
advisory committee established to provide advice to the Commissioner.
The Commissioner is charged with the administration of the
Radiation Control for Health and Safety Act of 1968. This Act creates
the Committee and requires the Commissioner to consult with the
Committee before prescribing standards for radiation emissions from
electronic products. This Committee provides advice and consultation to
the Commissioner on the technical feasibility, reasonableness, and
practicability of performance standards for electronic products to
control the emission of radiation from such products and may recommend
electronic product radiation safety standards to the Commissioner for
consideration.
The Committee shall consist of 15 voting members, including the
Chair. Members and the Chair are selected by the Commissioner or
designee from among authorities knowledgeable in the fields of science
or engineering applicable to electronic product radiation safety.
Members will be invited to serve for overlapping terms of up to 4
years. Voting members will include five members selected from
governmental agencies, including State and Federal Governments, five
members from the affected industries, and five members from the general
public, of which at least one shall be a representative of organized
labor. A quorum shall consist of 10 members, of which at least 3 shall
be from the general public, 3 from the government agencies, and 3 from
the affected industries.
Further information regarding the most recent charter and other
information can be found at https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Radiation-EmittingProducts/TechnicalElectronicProductRadiationSafetyStandardsCommittee/default.htm
or by contacting the Designated Federal Officer (see FOR FURTHER
INFORMATION CONTACT). In light of the fact that no change has been made
to the committee name or description of duties, no amendment will be
made to 21 CFR 14.100.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app.). For general information related to FDA advisory
committees, please visit us at https://www.fda.gov/AdvisoryCommittees/default.htm.
Dated: February 11, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2021-03239 Filed 2-17-21; 8:45 am]
BILLING CODE 4164-01-P
